Rituximab as First-Line Maintenance Therapy Following Rituximab-Containing Therapy for Follicular LymphomaProfile Report

被引：0
|
作者：
Jamie D. Croxtall
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
BioDrugs | 2011年 / 25卷
关键词：
Maintenance Therapy; Induction Therapy; Follicular Lymphoma; Observation Group; Progressive Multifocal Leukoencephalopathy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：329 / 331
页数：2
相关论文
共 50 条
  • [41] Modelling the Cost Effectiveness of Rituximab in Chronic Lymphocytic Leukaemia in First-Line Therapy and Following Relapse
    Adena, Michael
    Houltram, Jennifer
    Mulligan, Stephen P.
    Todd, Carlene
    Malanos, Grace
    PHARMACOECONOMICS, 2014, 32 (02) : 193 - 207
  • [42] First-line Combination Therapy with Rituximab and Corticosteroids is Effective and Safe for Pemphigus
    Cho, Yung-Tsu
    Lee, Fang-Yu
    Chu, Chia-Yu
    Wang, Li-Fang
    ACTA DERMATO-VENEREOLOGICA, 2014, 94 (04) : 472 - 473
  • [43] Rituximab in Neuromyelitis Optica Spectrum Disorders: Why Not as First-Line Therapy
    Kim, Su-Hyun
    Kim, Ho Jin
    JAMA NEUROLOGY, 2017, 74 (04) : 482 - 482
  • [44] Characteristics and outcomes of patients with relapsed follicular lymphoma following retreatment with second-line rituximab-containing chemotherapy
    Liu, Jiajia
    Stewart, Douglas
    Fontaine, Amelie
    Peters, Anthea
    Fleury, Isabelle
    Mollica, Luigina
    Prica, Anca
    Buckstein, Rena
    Sehn, Laurie
    Jiang, Aixiang
    Kuruvilla, John
    Villa, Diego
    LEUKEMIA & LYMPHOMA, 2020, 61 (10) : 2492 - 2496
  • [45] Efficacy and safety of rituximab as first-line therapy in NMOSD compared with other first-line immunosuppressive treatments
    Pouparti, J.
    Giovanelli, J.
    Deschamps, R.
    Durand-Dubief, F.
    Audoin, B.
    Ciron, J.
    Maillart, E.
    Papeix, C.
    Collongues, N.
    Bourre, B.
    Cohen, M.
    Wiertlewski, S.
    Laplaud, D.
    Brassat, D.
    Vukusic, S.
    Marignier, R.
    Zephir, H.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 474 - 475
  • [46] SAKK 35/14 trial: Rituximab with or without Ibrutinib for advanced follicular lymphoma in need of first-line therapy
    Novak, U.
    Ostenstad, B.
    Zander, T.
    Mingrone, W.
    Fischer, N.
    Rutti, M.
    Mey, U.
    Hitz, F.
    Rondeau, S.
    Vilei, S. Berardi
    Secondini, C.
    Wahlin, E.
    Zucca, E.
    SWISS MEDICAL WEEKLY, 2018, 148 : 4S - 4S
  • [47] Maintenance therapy with azathioprine prolonged duration of remission for pemphigus patients who received rituximab as first-line or add-on therapy
    Cho, Yung-Tsu
    Huang, Yu-Ming
    Wang, Li-Fang
    Chu, Chia-Yu
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2020, 119 (01) : 230 - 237
  • [48] PERSPECTIVE: A Randomized, Phase 3 Study of Ibrutinib-Rituximab Versus Placebo-Rituximab Combination Therapy for First-Line Treatment of Follicular Lymphoma
    Flinn, Ian
    Gordon, Leo
    Rule, Simon
    Chen, Robert
    Kwei, Long
    Chu, Alvina
    Fowler, Nathan
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 : S12 - S13
  • [49] Optimization of Postremission Therapy in Follicular Lymphoma: Efficacy of Rituximab Maintenance
    Roy, Rupali
    Gordon, Leo I.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2011, 9 (05): : 563 - 571
  • [50] Severe Anemia During Rituximab Maintenance Therapy for Follicular Lymphoma
    Liapis, Konstantinos
    Harhalakis, Nikolaos
    Stefanou, George
    Apostolidis, John
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (08) : E95 - E96
12345